INOVIO to Report Third Quarter 2024 Financial Results on November 14, 2024
PLYMOUTH MEETING, Pa., Nov. 6, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that third quarter 2024 financial results will be released after the market close on November 14, 2024. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update.
The live webcast will be available online at http://ir.inovio.com/events-and-presentations/default.aspx. This is a listen-only event but will include a live Q&A with analysts. The webcast will be archived and available for replay for 90 days following the event.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contacts
Media: Jennie Willson (267) 429-8567 jennie.willson@inovio.com
Investors: Thomas Hong (267) 440-4298 thomas.hong@inovio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-report-third-quarter-2024-financial-results-on-november-14-2024-302297260.html
SOURCE INOVIO Pharmaceuticals, Inc.
Nachrichten zu Inovio Pharmaceuticals Inc
Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv
Analysen zu Inovio Pharmaceuticals Inc
Datum | Rating | Analyst | |
---|---|---|---|
15.02.2018 | Inovio Pharmaceuticals Buy | Maxim Group | |
18.10.2017 | Inovio Pharmaceuticals Outperform | RBC Capital Markets | |
24.05.2017 | Inovio Pharmaceuticals Buy | Maxim Group | |
16.03.2017 | Inovio Pharmaceuticals Buy | Maxim Group | |
07.11.2016 | Inovio Pharmaceuticals Buy | Aegis Capital |
Datum | Rating | Analyst | |
---|---|---|---|
15.02.2018 | Inovio Pharmaceuticals Buy | Maxim Group | |
18.10.2017 | Inovio Pharmaceuticals Outperform | RBC Capital Markets | |
24.05.2017 | Inovio Pharmaceuticals Buy | Maxim Group | |
16.03.2017 | Inovio Pharmaceuticals Buy | Maxim Group | |
07.11.2016 | Inovio Pharmaceuticals Buy | Aegis Capital |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Inovio Pharmaceuticals Inc nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen